Search research articles
Contact Us
Filters
Showing results (51-60 of 67) with videos related to
Page
of 7
Sort By:
Leukemia & Lymphoma
|
November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Nicole Wong Doo, Philip A Thompson, H Miles Prince, et al.
Leukemia & Lymphoma
|
November 17, 2006
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma
Max Wolf, Mark Bentley, Paula Marlton, et al.
Science Advances
|
July 30, 2025
Better and faster decisions by larger fish shoals in the wild
Korbinian Pacher, David Bierbach, Yunus Sevinchan, et al.
Blood
|
July 10, 2008
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M Mead, Sharon L Barrans, Wendi Qian, et al.
Leukemia & Lymphoma
|
October 15, 2015
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy
Thomas E Lew, Chan Y Cheah, Dennis A Carney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
Marinus H J van Oers, Martine Van Glabbeke, Livia Giurgea, et al.
Leukemia & Lymphoma
|
February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
Andrew Wirth, Andrew Grigg, Max Wolf, et al.
Leukemia & Lymphoma
|
January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, et al.
Blood
|
July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
Marinus H J van Oers, Evelyn Tönnissen, Martine Van Glabbeke, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 67) with videos related to
Sort By:
Page
of 7
Leukemia & Lymphoma
|
November 6, 2012
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma
Nicole Wong Doo, Philip A Thompson, H Miles Prince, et al.
Leukemia & Lymphoma
|
November 17, 2006
Pegfilgrastim to support CHOP-14 in elderly patients with non-Hodgkin's lymphoma
Max Wolf, Mark Bentley, Paula Marlton, et al.
Science Advances
|
July 30, 2025
Better and faster decisions by larger fish shoals in the wild
Korbinian Pacher, David Bierbach, Yunus Sevinchan, et al.
Blood
|
July 10, 2008
A prospective clinicopathologic study of dose-modified CODOX-M/IVAC in patients with sporadic Burkitt lymphoma defined using cytogenetic and immunophenotypic criteria (MRC/NCRI LY10 trial)
Graham M Mead, Sharon L Barrans, Wendi Qian, et al.
Leukemia & Lymphoma
|
October 15, 2015
Dose-reduced fludarabine, cyclophosphamide and rituximab is well tolerated in older patients with chronic lymphocytic leukemia and has preserved therapeutic efficacy
Thomas E Lew, Chan Y Cheah, Dennis A Carney, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 5, 2010
Rituximab maintenance treatment of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study
Marinus H J van Oers, Martine Van Glabbeke, Livia Giurgea, et al.
Leukemia & Lymphoma
|
February 15, 2011
Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australasian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group
Andrew Wirth, Andrew Grigg, Max Wolf, et al.
Leukemia & Lymphoma
|
January 12, 2019
The effect of tyrosine kinase inhibitor interruption and interferon use on pregnancy outcomes and long-term disease control in chronic myeloid leukemia
Masa Lasica, Abbey Willcox, Kate Burbury, et al.
Blood
|
July 29, 2006
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H J van Oers, Richard Klasa, Robert E Marcus, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 7, 2010
BCL-2/IgH polymerase chain reaction status at the end of induction treatment is not predictive for progression-free survival in relapsed/resistant follicular lymphoma: results of a prospective randomized EORTC 20981 phase III intergroup study
Marinus H J van Oers, Evelyn Tönnissen, Martine Van Glabbeke, et al.
Page
of 7